Skip to content

A study of initial total hip replacement using a cementless hip implant that has been coated with a bio-active material.

Effectiveness of a porous titanium and hydroxyapatite plasma-sprayed short stem in total hip arthroplasty.

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000203257
Enrollment
222
Registered
2018-02-08
Start date
2018-03-01
Completion date
2020-02-28
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a prospective, multi-centre, clinical study using a product that has been registered for use in Australia by the TGA. The primary purpose of the study is to measure micro-movement of a cementless total hip replacement implant within the bone at timepoints up to three years. The micro-movement (if any) will be measured using X-Rays. 222 participants will be recruited and will be followed up for a period of three years. Quality of Life will also be analysed using two questionnaires.

Interventions

Primary total hip replacement with an uncemented femoral stem. The intervention is the hip replacement surgery which will be carried out by a suitably qualified and experienced orthopaedic surgeon. The intervention will be delivered once only for each participant and will take place in an operating theatre within a hospital setting

Sponsors

MAC Surgical
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Participants with symptomatic arthritis who are candidates for a primary total hip replacement with an uncemented femoral stem as determined jointly by the surgeon and the patient Age - 75 years or less Patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up period

Exclusion criteria

Patients with rheumatoid arthritis Patients with a history of active infection Patients with conditions or medications associated with osteoporosis or osteopenia Pregnant women or those seeking to become pregnant

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026